We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · January 14, 2020

Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Treated With Pembrolizumab

JAMA Oncology

 

Additional Info

JAMA Oncology
Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo: A Secondary Analysis of a Randomized Clinical Trial
JAMA Oncol 2020 Jan 02;[EPub Ahead of Print], AMM Eggermont, M Kicinski, CU Blank, M Mandala, GV Long, V Atkinson, S Dalle, A Haydon, A Khattak, MS Carlino, S Sandhu, J Larkin, S Puig, PA Ascierto, P Rutkowski, D Schadendorf, R Koornstra, L Hernandez-Aya, AM Di Giacomo, AJM van den Eertwegh, JJ Grob, R Gutzmer, R Jamal, PC Lorigan, C Krepler, N Ibrahim, S Marreaud, A van Akkooi, C Robert, S Suciu

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading